FDA panel: Standardised diagnostic tests needed for molecular indications
This article was originally published in Scrip
Executive Summary
The US FDA used a 22 March meeting of its oncologic drugs advisory committee (ODAC) to give a clear signal to drug developers: do not ask for approval of a new drug with a molecular indication unless it comes with a proven diagnostic for the targeted genetic anomaly.